Evidence map›Paper›PMID 39847410›Full record

ArticleJMIR research protocols2025

Comparative- and Cost-Effectiveness Research Determining the Optimal Intervention for Advancing Transgender Women With HIV to Full Viral Suppression (Text Me, Alexis!): Protocol for a Randomized Controlled Trial.

Cathy J Reback, Thomas Blue, Ali Jalali, Raphael Landovitz, Michael J Li, Raymond P Mata, Danielle Ryan, Philip J Jeng, Sean M Murphy

Abstract readClinical Trial Protocol
In one paragraph

Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cathy J Reback *Friends Research Institute, Inc., Baltimore, MD, United States.ORCID 0000-0003-4375-7452
Thomas Blue *Friends Research Institute, Inc., Baltimore, MD, United States.ORCID 0009-0006-5983-6218
Ali Jalali *Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.ORCID 0000-0003-4349-1519
Raphael Landovitz *Department of Family Medicine, University of California, Center for HIV Identification, Prevention and Treatment Services, Los Angeles, CA, United States.ORCID 0000-0002-1442-714X
Michael J Li *Department of Family Medicine, University of California, Center for HIV Identification, Prevention and Treatment Services, Los Angeles, CA, United States.ORCID 0000-0003-2457-604X
Raymond P Mata *Friends Research Institute, Inc., Baltimore, MD, United States.ORCID 0000-0002-2386-8086
Danielle Ryan *Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.ORCID 0000-0002-8423-3332
Philip J Jeng *Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.ORCID 0000-0002-8336-5536
Sean M Murphy *Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.ORCID 0000-0001-9104-0670

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Bruce R Schackman · 2015 to 2026
$20.7M
Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppressionR01DA056287 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI MURPHY, SEAN M., REBACK, CATHY J · 2023 to 2025
$2.5M
Trajectories of socially regulated gene expression, methamphetamine use, and viral load among HIV-positive men who have sex with men (MSM) receiving contingency managementK01DA051329 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, MICHAEL JONATHAN · 2021 to 2025
$947k
NIDA NIH HHS K01 DA051329NIDA NIH HHS P30 DA040500NIDA NIH HHS R01 DA056287NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

backgroundMany transgender women with HIV achieve suboptimal advancement through the HIV Care Continuum, including poor HIV health care usage, retention in HIV medical care, and rates of viral suppression. These issues are exacerbated by comorbid conditions, such as substance use disorder, which is also associated with reduced quality of life, increased overdose deaths, usage of high-cost health care services, engagement in a street economy, and cycles of incarceration. Thus, it is critical that efforts to End the HIV Epidemic include effective interventions to link and retain transgender women in HIV care through full viral suppression.

objectiveThis study builds on the promising findings from our two Health Resources and Services Administration-funded demonstration projects, The Alexis Project and Text Me, Girl!, which used peer health navigation (PHN) and SMS text messaging, respectively, for advancing transgender women with HIV to full viral suppression. Though the effectiveness of both interventions has been established, their comparative effectiveness, required resources or costs, cost-effectiveness, and heterogeneous effects on subgroups, including those with substance use disorder, have not been evaluated. Given the many negative personal and public health consequences of untreated or undertreated HIV, and that HIV services for transgender women are frequently delivered in resource-limited, community-based settings, a comprehensive economic evaluation is critical to inform decisions of stakeholders, such as providers, insurers, and policy makers.

methodsText Me, Alexis! is a 3-arm randomized controlled trial. Participants (N=195) will be randomized (1:1:1) into: PHN alone (n=65), SMS text messaging alone (n=65), or PHN+SMS text messaging (n=65). Using the same time points as the Health Resources and Services Administration demonstration projects, the repeated-measures design will assess participants at baseline, 3, 6, 12, and 18 months post randomization. Over the course of the 90 days, participants in the PHN arm will receive unlimited navigation sessions; participants in the SMS text messaging arm will receive 270 theory-based SMS text messages (3 messages daily) that are targeted, tailored, and personalized specifically for transgender women with HIV; and participants in the PHN+SMS text messaging arm will receive a combined PHN and SMS text message intervention. The desired outcome of Text Me, Alexis! is viral suppression and cost-effectiveness.

resultsRecruitment began on April 10, 2024, and the first participant was enrolled on April 11, 2024. Data collection is expected to be completed in July 2027. Primary outcome analyses will begin immediately following the conclusion of the follow-up evaluations.

conclusionsTransgender women are a high-priority population for reaching End the HIV Epidemic goals. Findings have the potential to improve individual and population health outcomes by generating significant improvements in viral suppression among transgender women and guiding service provision and public policy. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/65313.

Indexed as

HIV InfectionsText MessagingTransgender PersonsAdultComparative Effectiveness ResearchCost-Benefit AnalysisFemaleHumansMaleRandomized Controlled Trials as TopicViral LoadHIV/AIDSHIV Care Continuumpeer health navigationSMS text messagingtransgender women

Identifiers

PMID39847410
PMCPMC11803334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.